(Q34546035)

2 August 2017

1 reference

title

Imiquimod as a dermatological therapy (English)

1 reference

2 August 2017

Hue Tran

1

1 reference

2 August 2017

Gilberto Moreno

series ordinal

2

1 reference

2 August 2017

Stephen Shumack

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

5

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

427-438

1 reference

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Toll-like receptors: critical proteins linking innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Malignant transformation of solar keratoses to squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Cytokine profiles in spontaneously regressing basal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of Bowen's disease of the penis with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Successful topical immunotherapy of bowenoid papulosis with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Infantile hemangioma: clinical resolution with 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Treatment of granuloma annulare with topical 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.427

21 January 2018

Identifiers

DOI

10.1517/14656566.5.2.427

1 reference

2 August 2017

1 reference